The Sensitization of Melatonin in Osteosarcoma Cells by Suppression of Anti-Apoptotic Proteins

Mir, Seyed Mostafa; Yousefi, Bahman; Marjani, Abdoljalal; Rahimi, Mahdi; Qujeq, Durdi

doi:10.34172/ps.2020.3

Cited by 7 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…decreases the survival of MG63 and Saos2 OS cells and also promotes the therapeutic effect of DOX on OS cells through downregulating the expression of X-linked Inhibitor of Apoptosis (XIAP) and Survivin [30].…”

Section: Discussionmentioning

confidence: 99%

“…The combination of MLT with chemotherapy drugs, such as cisplatin or methotrexate, increases the survival rate of normal cells while decreasing the viability of cancer cells [29]. In this regard, Mir et al proposed that MLT in combination with doxorubicin (DOX) decreases the survival of MG63 and Saos2 OS cells and also promotes the therapeutic effect of DOX on OS cells through downregulating the expression of X-linked Inhibitor of Apoptosis (XIAP) and Survivin [30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin

et al. 2022

Self Cite

View full text Add to dashboard Cite

Chemotherapy, which is one of the common treatments for osteosarcoma (OS), has many side effects and in some cases has low effectiveness due to chemoresistance, hence it is vital to study new therapies for OS. In this regard, we combined melatonin with cisplatin and evaluate their effect on MG63 OS cells. Since melatonin has anti-cancer properties, we hypothesized that its combination with cisplatin could increase the effectiveness of cisplatin. Firstly, MTT assay was used to evaluate the cell viability and cytotoxicity of cisplatin on MG63 cells and the results showed that melatonin in combination with cisplatin increases the sensitivity of MG63 cells to cisplatin. In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Furthermore, analysis of Annexin V/FITC assay data revealed that the rate of apoptosis in MG63 OS cell line remarkably promoted after treated with cisplatin and melatonin combination. As a result, our findings show that melatonin in combination with cisplatin increases the effectiveness of cisplatin in osteosarcoma cells and this study provides a new therapeutic approach for OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 2 Currently, the standard systematic chemotherapeutic drugs for OS are: high-dose methotrexate with leucovorin rescue (HDMTX), doxorubicin, and cisplatin (MAP). 3 , 4 With the complete surgical resection, this adjuvant chemotherapy achieved 60–70% of 5-year event-free survival in patients with non-metastatic disease. 3 However, these three drugs are all cytotoxic agents with many side-effects, 5 including cardiotoxicity.…”

Section: Introductionmentioning

confidence: 99%

CircRNA hsa_circ_0005909 Promotes Cell Proliferation of Osteosarcoma Cells by Targeting miR-338-3p/HMGA1 Axis

Zhang¹,

Na²,

Liu³

et al. 2021

CMAR

View full text Add to dashboard Cite

Objective Osteosarcoma (OS) is the most common malignant bone tumor in the pediatric population. The main goal of this study is to investigate the role of hsa_circ_0005909 and the underlying signaling pathway involved in OS. Methods Cell proliferation was measured using a CCK-8 assay kit and clone formation assay. Change of RNA and protein expression was determined using RNA extract and quantitative real time PCR (RT-qPCR) assay and Western blotting, respectively. CircInteractome was used to predict the target of circRNA and starBase v2.0 was used to predict the target of miRNAs. Luciferase assay was used to confirm the predicted results from CircInteractome, starBase v2.0, and MirTarget2. Results Expression of circ_0005909 was upregulated in both OS tissues and cell lines. The predicted results from CircInteractome, starBase v2.0, and MirTarget2 demonstrated that circ_0005909 could sponge miR-338-3p and that HGMA1 was the direct target of miR-338-3p. Cell viability and cell clones were inhibited by knockdown of circ_0005909 but increased by dual inhibition of circ_0005909 and miR-338-3p. Phosphorylation of ERK, Akt, and PI3K was inhibited by sh-circ_0005909, while this inhibition was repressed by co-transfection of sh-circ_0005909 and HGMA1. Conclusion Expression of circ_0005909 was upregulated in both OS tissues and cell lines which upregulated expression of HGMA1 through sponging miR-338-3p, resulting in the activation of MAPK-ERK and PI3K-Akt signaling pathways to promote the development of OS.

show abstract

“…Other sources of melatonin secretion in the human body include the retina, gastrointestinal tract, leukocytes, bone marrow, and skin (3). Melatonin is recognized as a multitasking molecule with a wide variety of biological actions, including antioxidant effects (4,5), anti-inflammatory effects, immunomodulatory properties (6), osteopromotion, bone loss inhibition (7,8), oncostatic effects (9,10), and neuroprotective properties (11). This biomarker enhances osteoblast differentiation and bone formation via stim-ulating type I collagen synthesis.…”

Section: Introductionmentioning

confidence: 99%

Changes in Salivary Melatonin Levels by Scaling and Root Planing in Patients with Chronic Periodontitis

Purrahmani

Soghli

Qujeq

et al. 2021

J Kermanshah Univ Med Sci

Self Cite

View full text Add to dashboard Cite

Background: Periodontitis is a chronic inflammatory disease that causes tissue destruction due to the imbalance in the oxidant-antioxidant system. Melatonin has anti-inflammatory, antioxidant, and immune-modulatory properties and is considered to be a biomarker and diagnostic/therapeutic agent in the pathogenesis of periodontitis. Objectives: The present study aimed to evaluate the salivary melatonin level and its changes following non-surgical periodontal therapy in patients with periodontitis. Methods: In total, 90 salivary samples were collected from 60 patients, including 30 from patients with moderate chronic periodontitis (before periodontal treatment), and 30 from the same patients one month after the non-surgical periodontal therapy, and 30 from periodontally healthy subjects (control). Salivary melatonin levels were measured using the competitive immunoassay of the human melatonin ELISA kit. Results: The highest melatonin concentration was observed in the control group (79.55 ± 59.22; P < 0.05), while the lowest concentration was observed in the pre-treatment group (P < 0.05). In addition, salivary melatonin concentration in the post-treatment group (56.58 ± 46.48) was significantly higher compared to the pre-treatment group (17.25 ± 5.79; P < 0.05). Conclusions: According to the results, salivary melatonin levels improved after non-surgical periodontal therapy, which suggests the involvement of melatonin in the pathogenesis of periodontitis. However, the exact role of melatonin requires further investigation.

show abstract

The Sensitization of Melatonin in Osteosarcoma Cells by Suppression of Anti-Apoptotic Proteins

Cited by 7 publications

References 33 publications

Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin

Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin

CircRNA hsa_circ_0005909 Promotes Cell Proliferation of Osteosarcoma Cells by Targeting miR-338-3p/HMGA1 Axis

Changes in Salivary Melatonin Levels by Scaling and Root Planing in Patients with Chronic Periodontitis

Contact Info

Product

Resources

About